Skip to content

Study · Not a test of the peptide alone · 1998

7 results

High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.

Pica F, Fraschetti M, Matteucci C, Tuthill C, Rasi G

Anticancer research1 Sept 1998Cited by 28 (Europe PMC)

PMID9858941 (opens in a new tab)PepBankPUB-09858941
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with B16 melanoma, triple chemo-immunotherapy with high-dose thymosin alpha‑1 caused complete tumour regression for 27.5 days, 3.9 times longer than in untreated controls.

    In plain wordsIn mice, a three-drug treatment that included high-dose thymosin alpha‑1 kept B16 melanoma away longer than no treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseDuration of complete tumour regression
    Study

    mousen: not reported in source

    C57BL/6 mice with B16 melanoma
    Comparator
    All other groups
    Outcome group
    Tumor growth · Cancer

    Measurements

    Complete regression duration
    27.5 days
    HD-T alpha 1 chemo-immunotherapy
    Regression duration versus untreated controls
    3.9 times
    HD-T alpha 1 chemo-immunotherapy

    Source sentences

    Summary
    Chemo-immunotherapy with high dose (HD)-T alpha 1 caused complete tumour regression for 27.5 days after tumour cell injection (3.9 times longer than untreated controls)
    1 context sentence
    Summary · context
    C57BL/6 mice were challenged subcutaneously with B16 melanoma cells and injected intraperitoneally with saline, CY (200 mg/kg, day 7), or CY with T alpha 1 (200, 600 or 6000 micrograms/kg/day, days 10-13) and IFN alpha beta (30,000 I.U., day 13).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with B16 melanoma, triple chemo-immunotherapy with high-dose thymosin alpha‑1 delayed tumour relapse compared with all other groups.

    In plain wordsIn mice, a three-drug treatment that included high-dose thymosin alpha‑1 delayed melanoma relapse compared with the other groups.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumour relapse
    Study

    mousen: not reported in source

    C57BL/6 mice with B16 melanoma
    Comparator
    All other groups
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    and delayed tumour relapse compared to all other groups.
    1 context sentence
    Summary · context
    C57BL/6 mice were challenged subcutaneously with B16 melanoma cells and injected intraperitoneally with saline, CY (200 mg/kg, day 7), or CY with T alpha 1 (200, 600 or 6000 micrograms/kg/day, days 10-13) and IFN alpha beta (30,000 I.U., day 13).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with B16 melanoma, triple chemo-immunotherapy with high-dose thymosin alpha‑1 significantly increased the median survival time.

    In plain wordsIn mice, a three-drug treatment that included high-dose thymosin alpha‑1 lengthened median survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMedian survival time
    Study

    mousen: not reported in source

    C57BL/6 mice with B16 melanoma
    Comparator
    All other groups
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    Moreover, it significantly increased the median survival time of treated mice
    1 context sentence
    Summary · context
    C57BL/6 mice were challenged subcutaneously with B16 melanoma cells and injected intraperitoneally with saline, CY (200 mg/kg, day 7), or CY with T alpha 1 (200, 600 or 6000 micrograms/kg/day, days 10-13) and IFN alpha beta (30,000 I.U., day 13).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with B16 melanoma, triple chemo-immunotherapy with high-dose thymosin alpha‑1 cured an average of 23% of animals, while none was cured in any other group.

    In plain wordsIn mice, a three-drug treatment that included high-dose thymosin alpha‑1 cured some animals; no other group had cures.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseProportion of animals cured
    Study

    mousen: not reported in source

    C57BL/6 mice with B16 melanoma
    Comparator
    All other groups
    Outcome group
    Tumor growth · Cancer

    Measurements

    Cure rate
    23%
    HD-T alpha 1 chemo-immunotherapy

    Source sentences

    Summary
    and cured an average of 23% of animals, while none was cured in any other group.
    1 context sentence
    Summary · context
    C57BL/6 mice were challenged subcutaneously with B16 melanoma cells and injected intraperitoneally with saline, CY (200 mg/kg, day 7), or CY with T alpha 1 (200, 600 or 6000 micrograms/kg/day, days 10-13) and IFN alpha beta (30,000 I.U., day 13).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In mice with B16 melanoma, splenocytes from mice given triple therapy with high-dose thymosin alpha‑1 had increased cytotoxic activity against YAC-l and autologous B16 tumour cells.

    In plain wordsIn mice, spleen cells from animals given a three-drug treatment with high-dose thymosin alpha‑1 killed more tumour cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSplenocyte cytotoxic activity
    Study

    mousen: not reported in source

    C57BL/6 mice with B16 melanoma
    Comparator
    All other groups
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Splenocytes from HD-T alpha 1-treated mice showed markedly increased cytotoxic activities against both YAC-l and autologous B16 tumour cells.
    1 context sentence
    Summary · context
    C57BL/6 mice were challenged subcutaneously with B16 melanoma cells and injected intraperitoneally with saline, CY (200 mg/kg, day 7), or CY with T alpha 1 (200, 600 or 6000 micrograms/kg/day, days 10-13) and IFN alpha beta (30,000 I.U., day 13).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In mice with B16 melanoma, triple therapy with high-dose thymosin alpha‑1 reversed the tumour-induced reduction in percentages of CD3 and CD4-positive splenocytes to non-tumour levels.

    In plain wordsIn mice, a three-drug treatment with high-dose thymosin alpha‑1 brought tumour-lowered T-cell percentages back to normal levels.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD3 and CD4-positive splenocyte percentages
    Study

    mousen: not reported in source

    C57BL/6 mice with B16 melanoma
    Comparator
    All other groups
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    HD-T alpha 1 treatment reversed the tumour-induced reduction in percentages of CD3 and CD4-positive splenocytes to non-tumour levels
    1 context sentence
    Summary · context
    C57BL/6 mice were challenged subcutaneously with B16 melanoma cells and injected intraperitoneally with saline, CY (200 mg/kg, day 7), or CY with T alpha 1 (200, 600 or 6000 micrograms/kg/day, days 10-13) and IFN alpha beta (30,000 I.U., day 13).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In mice with B16 melanoma, triple therapy with high-dose thymosin alpha‑1 increased percentages of CD8, B220 and IL-2R beta-positive cells beyond non-tumour controls.

    In plain wordsIn mice, a three-drug treatment with high-dose thymosin alpha‑1 raised several immune-cell percentages above those of tumour-free controls.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD8, B220 and IL-2R beta-positive splenocyte percentages
    Study

    mousen: not reported in source

    C57BL/6 mice with B16 melanoma
    Comparator
    All other groups
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    and it increased percentages of CD8, B220 and IL-2R beta-positive cells to well beyond non-tumour controls.
    1 context sentence
    Summary · context
    C57BL/6 mice were challenged subcutaneously with B16 melanoma cells and injected intraperitoneally with saline, CY (200 mg/kg, day 7), or CY with T alpha 1 (200, 600 or 6000 micrograms/kg/day, days 10-13) and IFN alpha beta (30,000 I.U., day 13).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.